Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors

被引：8

作者：

Pasi, K. John ^{[1
]}

Georgiev, Pencho ^{[2
]}

Mant, Tim ^{[3
]}

Lissitchkov, Toshko ^{[4
]}

Creagh, Michael Desmond ^{[5
]}

Bevan, David ^{[6
]}

Austin, Steve ^{[7
]}

Hay, Charles R. ^{[8
]}

Hegemann, Inga ^{[9
]}

Kazmi, Rashid ^{[10
]}

Chowdary, Pratima ^{[11
,12
]}

Ragni, Margaret V. ^{[13
,14
]}

Soh, Chang-Heok ^{[15
]}

Akinc, Akin ^{[15
]}

Partisano, Angela M. ^{[15
]}

Sorenson, Benny ^{[15
]}

Rangarajan, Savita ^{[16
]}

机构：

[1] Barts & London Queen Marys Sch Med & Dent, Royal London Haemophilia Ctr, London, England

[2] Univ Multiprofile Hosp Act Treatment Sveti Georgi, Plovdiv, Bulgaria

[3] Quintiles Drug Res Unit, London, England

[4] SHAT Joan Pavel, Dept Coagulat Disorders & Anemia, Sofia, Bulgaria

[5] Royal Cornwall Hosp NHS Trust, Truro, England

[6] Guys & St Thomas Hosp NHS Trust, London, England

[7] St Georges Univ Hosp NHS Fdn Trust, St Georges Haemophilia Ctr, London, England

[8] Manchester Royal Infirm, Manchester, Lancs, England

[9] Univ Hosp, Zurich, Switzerland

[10] Univ Hosp Southampton NHS Fdn Trust, Southampton, Hants, England

[11] Royal Free Hosp, KD Haemophilia Ctr, London, England

[12] Royal Free Hosp, Thrombosis Unit, London, England

[13] Univ Pittsburgh, Div Hematol Oncol, Dept Med, Med Ctr, Pittsburgh, PA USA

[14] Univ Pittsburgh, Hemophilia Ctr Western PA, Med Ctr, Pittsburgh, PA USA

[15] Alnylam Pharmaceut, Cambridge, MA USA

[16] Guys & St Thomas NHS Fdn Trust, Ctr Haemostasis Thrombosis, London, England

来源：

BLOOD | 2016年 / 128卷 / 22期

关键词：

D O I：

10.1182/blood.V128.22.1397.1397

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1397

引用

页数：6

共 50 条

[41] LONG-TERM SAFETY AND EFFICACY OF FITUSIRAN PROPHYLAXIS IN A PHASE 1/2 OPEN-LABEL EXTENSION STUDY IN PEOPLE WITH MODERATE OR SEVERE HEMOPHILIA A OR B
Pipe, Steven W.
Lissitchkov, Toshko
Mangles, Sarah
Georgiev, Pencho
Feng, Erin
Menapace, Laurel A.
Kichou, Salim
Andersson, Shauna
Demissie, Marek
Ragni, Margaret
AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 99 - 100
[42] PEGTIBATINASE, AN INVESTIGATIONAL ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF CLASSICAL HOMOCYSTINURIA: INITIAL RESULTS FROM THE PHASE 1/2 COMPOSE STUDY
Levy, Harvey L.
Thomas, Janet
Ficicioglu, Can
Lah, Melissa
Ganesh, Jaya
Sellos-Moura, Marcia
Bublil, Erez M.
Wilkening, Elizabeth
Guner, Jale
Chen, Ying
Greblikas, Feriandas
Vaidya, Sagar A.
MOLECULAR GENETICS AND METABOLISM, 2022, 135 (04) : 283 - 284
[43] Phase 2 Open-Label Extension Study of Patisiran, an RNAi Therapeutic for the Treatment of Familial Amyloidotic Polyneuropathy
Adams, David
Suhr, Ole
Coelho, Teresa
Conceicao, Isabel
Waddington-Cruz, Marcia
Schmidt, Hartmut
Buades, Juan
Campistol, Josep
Pouget, Jean
Berk, John
Falzone, Rick
Harrop, Jamie
De Frutos, Ricardo
Bettencourt, Brian
Cehelsky, Jeffrey
Nochur, Sara
Vaishnaw, Akshay
Gollob, Jared
ANNALS OF NEUROLOGY, 2014, 76 : S113 - S113
[44] ILLUMINATE-A, a phase 3 study of lumasiran, an investigational RNAi therapeutic, in children and adults with primary hyperoxaluria type 1 (PH1)
Garrelfs, Sander
Frishberg, Yaacov
Hulton, Sally
Koren, Michael
O'Riordan, William
Cochat, Pierre
Deschenes, Georges
Shasha-Lavsky, Hadas
Saland, Jeffrey
van't Hoff, William
Fuster, Daniel G.
Magen, Daniella
Moochhala, Shabbir
Schalk, Gesa
Simkova, Eva
Groothoff, Jaap
Sas, David
Meliambro, Kristin
Lu, Jiandong
Garg, Pushkal
Gansner, John
McGregor, Tracy
Lieske, John
SWISS MEDICAL WEEKLY, 2020, : 8S - 8S
[45] ILLUMINATE-A, A PHASE 3 STUDY OF LUMASIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC, IN CHILDREN AND ADULTS WITH PRIMARY HYPEROXALURIA TYPE 1 (PH1)
Garrelfs, Sander
Frishberg, Yaacov
Hulton, Sally
Koren, Michael
O'Riordan, William
Cochat, Pierre
Deschenes, Georges
Shasha-Laysky, Hadas
Saland, Jeffrey
Van't Hoff, William
Fuster, Daniel Guido
Magen, Daniella
Moochhala, Shabbir
Schalk, Gesa
Simkova, Eva
Groothoff, Jaap
Sas, David
Meliambro, Kristin
Lu, Jiandong
Garg, Pushkal
Gansner, John
McGregor, Tracy
Lieske, John
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 2183 - 2183
[46] Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma
Ducreux, M.
Abou-Alfa, G.
Ren, Z.
Edeline, J.
Li, Z.
Assenat, E.
Rimassa, L.
Blanc, J.
Ross, P.
Fang, W.
Hu, S.
Zhang, T.
Tran, A.
Pan, H.
Yen, C.
Wu, J.
Li, V.
Chica-Duque, S.
Merle, P.
Cheng, A.
ANNALS OF ONCOLOGY, 2021, 32 : S217 - S217
[47] Updated efficacy and safety results from phase 1 and phase 2 studies for AVR-RD-01, an investigational lentiviral gene therapy for Fabry disease
Thomas, Mark
MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S119 - S119
[48] Updated Results from a Phase 1 Study of TAK-659, an Investigational and Reversible SYK Inhibitor, in Patients (Pts) with Advanced Solid Tumor or Lymphoma Malignancies
Kaplan, Jason B.
Gordon, Leo I.
Infante, Jeffrey R.
Popat, Rakesh
Rambaldi, Alessandro
Madan, Sumit
Patel, Manish R.
Gritti, Giuseppe
Ng, Chin-Hin
Chau, Ian
Radford, John A.
de Oteyza, Jaime Perez
Zinzani, Pier Luigi
Faucette, Stephanie
Sheldon-Waniga, Emily
Williams, Miguel
Stumpo, Kate
Shou, Yaping
Carpio, Cecilia
Bosch, Francesc
BLOOD, 2016, 128 (22)
[49] Phase 1 Study of MLN9708, an Investigational Proteasome Inhibitor, in Advanced Nonhematologic Malignancies- Updated Results
Smith, D. C.
Infante, J. R.
Siu, L. L.
Sullivan, D.
Vlahovic, G.
Kauh, J.
Blakemore, S. J.
Gupta, N.
Kalebic, T.
Thompson, J. A.
EUROPEAN JOURNAL OF CANCER, 2011, 47 : S147 - S147
[50] Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
Shima, Midori
Hanabusa, Hideji
Taki, Masashi
Matsushita, Tadashi
Sato, Tetsuji
Fukutake, Katsuyuki
Kasai, Ryu
Yoneyama, Koichiro
Yoshida, Hiroki
Nogami, Keiji
BLOOD ADVANCES, 2017, 1 (22) : 1891 - 1899

← 1 2 3 4 5 →